Role of topoisomerase II beta in the resistance of 9-OH-ellipticine-resistant Chinese hamster fibroblasts to topoisomerase II inhibitors.
In the Chinese hamster lung cell line DC-3F/9-OH-E, made resistant to 9-OH-ellipticine and cross-resistant to other topoisomerase II inhibitors, the amount of topoisomerase II alpha is 4-5-fold lower than in the parental DC-3F cells. A mutation in position 1710 of topoisomerase II beta cDNA, generating a stop codon, completely abolishes the expression of this isoform in DC-3F/9-OH-E cells. To analyze the contribution of the loss of topoisomerase II beta to the resistance phenotype, DC-3F/9-OH-E cells were cotransfected with two plasmids, one conferring the resistance to G418, the other carrying the topoisomerase II beta cDNA. Among 200 G418-resistant clones, one was found to contain a topoisomerase II beta activity similar to that in the parental cells. These cells constitute an in vivo mammalian model to study the pharmacological role of topoisomerase II beta. In the transfected cells, different levels of cleavable complex formation and resistance reversion were observed with each topoisomerase II inhibitor examined. This work demonstrates that topoisomerase II beta is a pharmacological target for 9-OH-ellipticine, etoposide, or 4'-(9-acridinylamino)methanesulfon-m-anisidide and plays a role in the cytotoxicity of these agents. Furthermore, topoisomerase II beta is the preferential target for 4'-(9-acridinylamino)methanesulfon-m-anisidide. The loss of topoisomerase II beta activity in the DC-3F/9-OH-E cells is then in part responsible for their resistance to topoisomerase II inhibitors.
Dereuddre
S
S
URA147 Centre National de la Recherche Scientifique, Physicochimie et Pharmacologie des Macromolécules Biologiques, Unité de Biochimie-Enzymologie, Institut Gustave Roussy, Villejuif, France.
Delaporte
C
C
Jacquemin-Sablon
A
A
D000677:Amsacrine / Q000494:pharmacology; D000818:Animals; D002460:Cell Line; D003062:Codon / Q000235:genetics; D006224:Cricetinae; D003412:Cricetulus; D004250:DNA Topoisomerases, Type II / Q000235:genetics / Q000502:physiology; D019008:Drug Resistance, Neoplasm; D004611:Ellipticines / Q000494:pharmacology*; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D005047:Etoposide / Q000494:pharmacology; D005347:Fibroblasts / Q000187:drug effects* / Q000201:enzymology; D019833:Genistein / Q000494:pharmacology; D007527:Isoenzymes / Q000037:antagonists & inhibitors* / Q000235:genetics / Q000502:physiology; D008168:Lung; D059005:Topoisomerase II Inhibitors
D003062:Codon; D004611:Ellipticines; D004791:Enzyme Inhibitors; D007527:Isoenzymes; D059005:Topoisomerase II Inhibitors; D000677:Amsacrine; D005047:Etoposide; C008009:9-hydroxyellipticine; D019833:Genistein; D004250:DNA Topoisomerases, Type II